Telix Pharmaceuticals Limited (NASDAQ: TLX) Stock Competitors & Peer Comparison
See TLX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TLX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TLX | $10.69 | +1.14% | 3.6B | 111.59 | $0.10 | N/A |
| VRTX | $499.74 | -1.77% | 126.7B | 26.26 | $19.03 | N/A |
| MRNA | $218.01 | -7.82% | 87B | -26.75 | -$8.15 | N/A |
| REGN | $790.74 | -0.70% | 81.4B | 17.33 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $819.14 | -3.21% | 51.5B | 29.53 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $369.06 | -1.34% | 39.4B | 64.98 | $5.68 | N/A |
| RVMD | $177.96 | -5.97% | 38.1B | -20.18 | -$8.82 | N/A |
| RVMDW | $8.40 | -13.98% | 34.8B | -0.95 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TLX vs VRTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, VRTX has a market cap of 126.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while VRTX trades at $499.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas VRTX's P/E ratio is 26.26. In terms of profitability, TLX's ROE is +0.07%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, TLX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
TLX vs MRNA Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, MRNA has a market cap of 87B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while MRNA trades at $218.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas MRNA's P/E ratio is -26.75. In terms of profitability, TLX's ROE is +0.07%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TLX vs REGN Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, REGN has a market cap of 81.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while REGN trades at $790.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas REGN's P/E ratio is 17.33. In terms of profitability, TLX's ROE is +0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TLX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
TLX vs VRNA Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TLX's ROE is +0.07%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, TLX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TLX vs ARGX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ARGX has a market cap of 51.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ARGX trades at $819.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ARGX's P/E ratio is 29.53. In terms of profitability, TLX's ROE is +0.07%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, TLX is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
TLX vs SGEN Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TLX's ROE is +0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TLX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
TLX vs ONC Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ONC has a market cap of 39.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ONC trades at $369.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ONC's P/E ratio is 64.98. In terms of profitability, TLX's ROE is +0.07%, compared to ONC's ROE of +0.14%. Regarding short-term risk, TLX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ONC's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TLX vs RVMD Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RVMD has a market cap of 38.1B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RVMD trades at $177.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RVMD's P/E ratio is -20.18. In terms of profitability, TLX's ROE is +0.07%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TLX vs RVMDW Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RVMDW has a market cap of 34.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RVMDW trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RVMDW's P/E ratio is -0.95. In terms of profitability, TLX's ROE is +0.07%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TLX vs ALNY Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ALNY has a market cap of 31B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ALNY trades at $231.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ALNY's P/E ratio is 41.79. In terms of profitability, TLX's ROE is +0.07%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TLX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TLX vs ROIV Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ROIV has a market cap of 24.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ROIV trades at $33.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ROIV's P/E ratio is -31.90. In terms of profitability, TLX's ROE is +0.07%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, TLX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
TLX vs INCY Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, INCY has a market cap of 22.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while INCY trades at $113.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas INCY's P/E ratio is 15.20. In terms of profitability, TLX's ROE is +0.07%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TLX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for TLX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TLX vs UTHR Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, UTHR has a market cap of 22.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while UTHR trades at $533.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas UTHR's P/E ratio is 19.07. In terms of profitability, TLX's ROE is +0.07%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, TLX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
TLX vs GMAB Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, GMAB has a market cap of 22.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while GMAB trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas GMAB's P/E ratio is 27.87. In terms of profitability, TLX's ROE is +0.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for TLX.Check GMAB's competition here
BioNTech SE (NASDAQ: BNTX)
TLX vs BNTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, BNTX has a market cap of 21.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while BNTX trades at $87.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas BNTX's P/E ratio is -11.37. In terms of profitability, TLX's ROE is +0.07%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
TLX vs INSM Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, INSM has a market cap of 21B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while INSM trades at $96.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas INSM's P/E ratio is -23.42. In terms of profitability, TLX's ROE is +0.07%, compared to INSM's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TLX vs BGNE Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TLX's ROE is +0.07%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, TLX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TLX vs DNA-WT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TLX's ROE is +0.07%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, TLX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TLX vs EXEL Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, EXEL has a market cap of 15.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while EXEL trades at $62.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas EXEL's P/E ratio is 17.78. In terms of profitability, TLX's ROE is +0.07%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, TLX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TLX vs ASND Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ASND trades at $225.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ASND's P/E ratio is -93.07. In terms of profitability, TLX's ROE is +0.07%, compared to ASND's ROE of +1.90%. Regarding short-term risk, TLX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ASND's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TLX vs HALO Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, HALO has a market cap of 13.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while HALO trades at $121.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas HALO's P/E ratio is 22.73. In terms of profitability, TLX's ROE is +0.07%, compared to HALO's ROE of +1.81%. Regarding short-term risk, TLX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for TLX.Check HALO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TLX vs NBIX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, NBIX has a market cap of 13.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while NBIX trades at $135.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas NBIX's P/E ratio is 19.61. In terms of profitability, TLX's ROE is +0.07%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TLX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TLX vs JAZZ Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, JAZZ has a market cap of 13.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while JAZZ trades at $210.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas JAZZ's P/E ratio is 7.84. In terms of profitability, TLX's ROE is +0.07%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, TLX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for TLX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TLX vs BBIO Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while BBIO trades at $66.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas BBIO's P/E ratio is -17.75. In terms of profitability, TLX's ROE is +0.07%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, TLX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TLX vs KRTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TLX's ROE is +0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TLX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check KRTX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TLX vs SMMT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while SMMT trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas SMMT's P/E ratio is -13.06. In terms of profitability, TLX's ROE is +0.07%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TLX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SMMT's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TLX vs TECH Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while TECH trades at $72.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas TECH's P/E ratio is 37.41. In terms of profitability, TLX's ROE is +0.07%, compared to TECH's ROE of +0.09%. Regarding short-term risk, TLX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TLX vs RNAM Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TLX's ROE is +0.07%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, TLX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TLX vs BMRN Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while BMRN trades at $54.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas BMRN's P/E ratio is 26.30. In terms of profitability, TLX's ROE is +0.07%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, TLX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TLX vs MDGL Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, MDGL has a market cap of 10.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while MDGL trades at $449.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas MDGL's P/E ratio is -35.12. In terms of profitability, TLX's ROE is +0.07%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TLX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MDGL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TLX vs PCVX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, PCVX has a market cap of 9.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while PCVX trades at $63.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas PCVX's P/E ratio is -8.34. In terms of profitability, TLX's ROE is +0.07%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, TLX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TLX vs IBRX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, IBRX has a market cap of 9.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while IBRX trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas IBRX's P/E ratio is -9.46. In terms of profitability, TLX's ROE is +0.07%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, TLX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IBRX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TLX vs RXDX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TLX's ROE is +0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TLX vs KRYS Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, KRYS has a market cap of 9.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while KRYS trades at $316.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas KRYS's P/E ratio is 39.67. In terms of profitability, TLX's ROE is +0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KRYS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TLX vs NUVL Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TLX's ROE is +0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TLX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TLX.Check NUVL's competition here
10x Genomics, Inc. (NASDAQ: TXG)
TLX vs TXG Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, TXG has a market cap of 9.1B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while TXG trades at $69.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas TXG's P/E ratio is -118.41. In terms of profitability, TLX's ROE is +0.07%, compared to TXG's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TXG's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TLX vs CRNX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CRNX's P/E ratio is -16.86. In terms of profitability, TLX's ROE is +0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TLX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CRNX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
TLX vs TWST Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, TWST has a market cap of 8.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while TWST trades at $132.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas TWST's P/E ratio is -59.80. In terms of profitability, TLX's ROE is +0.07%, compared to TWST's ROE of -0.30%. Regarding short-term risk, TLX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TWST's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TLX vs IMGN Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TLX's ROE is +0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TLX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TLX vs CAI Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CAI has a market cap of 8.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CAI trades at $30.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CAI's P/E ratio is 85.87. In terms of profitability, TLX's ROE is +0.07%, compared to CAI's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CAI's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TLX vs KYMR Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, KYMR has a market cap of 8.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while KYMR trades at $104.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas KYMR's P/E ratio is -32.73. In terms of profitability, TLX's ROE is +0.07%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, TLX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KYMR's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TLX vs CYTK Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CYTK trades at $61.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CYTK's P/E ratio is -8.58. In terms of profitability, TLX's ROE is +0.07%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, TLX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CYTK's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TLX vs APGE Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas APGE's P/E ratio is -31.19. In terms of profitability, TLX's ROE is +0.07%, compared to APGE's ROE of -0.30%. Regarding short-term risk, TLX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TLX vs BPMC Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TLX's ROE is +0.07%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TLX.Check BPMC's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TLX vs PTGX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, PTGX has a market cap of 8.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while PTGX trades at $128.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas PTGX's P/E ratio is 125.00. In terms of profitability, TLX's ROE is +0.07%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, TLX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PTGX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
TLX vs TGTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while TGTX trades at $53.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas TGTX's P/E ratio is 19.55. In terms of profitability, TLX's ROE is +0.07%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, TLX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TGTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TLX vs AXSM Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, AXSM has a market cap of 8.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while AXSM trades at $157.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas AXSM's P/E ratio is -41.01. In terms of profitability, TLX's ROE is +0.07%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, TLX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check AXSM's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TLX vs CERE Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CERE's P/E ratio is -16.47. In terms of profitability, TLX's ROE is +0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TLX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CERE's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TLX vs ARWR Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ARWR has a market cap of 7.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ARWR trades at $55.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ARWR's P/E ratio is -24.85. In terms of profitability, TLX's ROE is +0.07%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, TLX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ARWR's competition here
Metsera, Inc. (NASDAQ: MTSR)
TLX vs MTSR Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TLX's ROE is +0.07%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, TLX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MTSR's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TLX vs SYRE Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, SYRE has a market cap of 7.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while SYRE trades at $79.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas SYRE's P/E ratio is -40.97. In terms of profitability, TLX's ROE is +0.07%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SYRE's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TLX vs IONS Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, IONS has a market cap of 7.1B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while IONS trades at $42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas IONS's P/E ratio is -13.13. In terms of profitability, TLX's ROE is +0.07%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IONS's competition here
Merus N.V. (NASDAQ: MRUS)
TLX vs MRUS Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TLX's ROE is +0.07%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRUS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TLX vs PRAX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while PRAX trades at $241.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas PRAX's P/E ratio is -18.70. In terms of profitability, TLX's ROE is +0.07%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, TLX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRAX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TLX vs ACLX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TLX's ROE is +0.07%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, TLX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TLX vs RETA Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RETA's P/E ratio is -66.29. In terms of profitability, TLX's ROE is +0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TLX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RETA's competition here
Abivax S.A. (NASDAQ: ABVX)
TLX vs ABVX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ABVX trades at $88.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ABVX's P/E ratio is -14.44. In terms of profitability, TLX's ROE is +0.07%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, TLX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ABVX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TLX vs CNTA Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TLX's ROE is +0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TLX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CNTA's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
TLX vs IOVA Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, IOVA has a market cap of 6.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while IOVA trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas IOVA's P/E ratio is -18.66. In terms of profitability, TLX's ROE is +0.07%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, TLX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IOVA's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TLX vs TERN Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas TERN's P/E ratio is -51.41. In terms of profitability, TLX's ROE is +0.07%, compared to TERN's ROE of -0.14%. Regarding short-term risk, TLX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TERN's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TLX vs RYTM Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RYTM trades at $86.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RYTM's P/E ratio is -27.71. In terms of profitability, TLX's ROE is +0.07%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RYTM's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TLX vs LGND Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while LGND trades at $295.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas LGND's P/E ratio is 32.44. In terms of profitability, TLX's ROE is +0.07%, compared to LGND's ROE of +0.20%. Regarding short-term risk, TLX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for TLX.Check LGND's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TLX vs BLTE Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while BLTE trades at $142.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas BLTE's P/E ratio is -76.47. In terms of profitability, TLX's ROE is +0.07%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, TLX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BLTE's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TLX vs CDTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TLX's ROE is +0.07%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, TLX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
TLX vs ABCM Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TLX's ROE is +0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TLX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ABCM's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TLX vs IMVT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while IMVT trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas IMVT's P/E ratio is -9.48. In terms of profitability, TLX's ROE is +0.07%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, TLX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IMVT's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TLX vs ISEE Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TLX's ROE is +0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TLX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ISEE's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
TLX vs KOD Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, KOD has a market cap of 5.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while KOD trades at $85.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas KOD's P/E ratio is -20.56. In terms of profitability, TLX's ROE is +0.07%, compared to KOD's ROE of -2.73%. Regarding short-term risk, TLX is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KOD's competition here
CG Oncology Inc. (NASDAQ: CGON)
TLX vs CGON Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CGON trades at $59.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CGON's P/E ratio is -22.25. In terms of profitability, TLX's ROE is +0.07%, compared to CGON's ROE of -0.25%. Regarding short-term risk, TLX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CGON's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TLX vs APLS Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas APLS's P/E ratio is 38.35. In terms of profitability, TLX's ROE is +0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TLX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APLS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TLX vs MIRM Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while MIRM trades at $80.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas MIRM's P/E ratio is -5.51. In terms of profitability, TLX's ROE is +0.07%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, TLX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TLX vs COGT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while COGT trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas COGT's P/E ratio is -13.99. In terms of profitability, TLX's ROE is +0.07%, compared to COGT's ROE of -0.73%. Regarding short-term risk, TLX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TLX vs PTCT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, PTCT has a market cap of 4.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while PTCT trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas PTCT's P/E ratio is -25.42. In terms of profitability, TLX's ROE is +0.07%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TLX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TLX vs SRRK Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, SRRK has a market cap of 4.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while SRRK trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas SRRK's P/E ratio is -11.57. In terms of profitability, TLX's ROE is +0.07%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, TLX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SRRK's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TLX vs CRSP Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CRSP trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CRSP's P/E ratio is -10.35. In terms of profitability, TLX's ROE is +0.07%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CRSP's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TLX vs ORKA Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ORKA has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ORKA trades at $71.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ORKA's P/E ratio is -37.08. In terms of profitability, TLX's ROE is +0.07%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, TLX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ORKA's competition here
Erasca, Inc. (NASDAQ: ERAS)
TLX vs ERAS Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ERAS trades at $13.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ERAS's P/E ratio is -14.40. In terms of profitability, TLX's ROE is +0.07%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TLX vs TVTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas TVTX's P/E ratio is -110.22. In terms of profitability, TLX's ROE is +0.07%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, TLX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TLX vs FOLD Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TLX's ROE is +0.07%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, TLX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TLX.Check FOLD's competition here
Veradermics, Incorporated (NYSE: MANE)
TLX vs MANE Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while MANE trades at $108.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas MANE's P/E ratio is -34.64. In terms of profitability, TLX's ROE is +0.07%, compared to MANE's ROE of -0.38%. Regarding short-term risk, TLX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MANE's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TLX vs AKRO Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TLX's ROE is +0.07%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, TLX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TLX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TLX vs ALPN Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TLX's ROE is +0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TLX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TLX vs DFTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, DFTX has a market cap of 4.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while DFTX trades at $32.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas DFTX's P/E ratio is N/A. In terms of profitability, TLX's ROE is +0.07%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, TLX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DFTX's competition here
Opthea Limited (NASDAQ: OPT)
TLX vs OPT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas OPT's P/E ratio is -1.52. In terms of profitability, TLX's ROE is +0.07%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TLX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TLX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
TLX vs PRTC Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TLX's ROE is +0.07%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TLX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TLX vs MRTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TLX's ROE is +0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TLX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TLX vs DNTH Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while DNTH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas DNTH's P/E ratio is -17.39. In terms of profitability, TLX's ROE is +0.07%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, TLX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNTH's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TLX vs EWTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while EWTX trades at $37.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas EWTX's P/E ratio is -20.10. In terms of profitability, TLX's ROE is +0.07%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EWTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TLX vs CPRX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CPRX's P/E ratio is 17.49. In terms of profitability, TLX's ROE is +0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TLX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CPRX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TLX vs ADPT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ADPT has a market cap of 3.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ADPT trades at $24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ADPT's P/E ratio is -58.59. In terms of profitability, TLX's ROE is +0.07%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, TLX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ADPT's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
TLX vs ABCL Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ABCL trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ABCL's P/E ratio is -21.85. In terms of profitability, TLX's ROE is +0.07%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, TLX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
TLX vs RYZB Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TLX's ROE is +0.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TLX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
TLX vs CBAY Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TLX's ROE is +0.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TLX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CBAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
TLX vs TNGX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while TNGX trades at $22.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas TNGX's P/E ratio is -26.55. In terms of profitability, TLX's ROE is +0.07%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, TLX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TNGX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
TLX vs ARQT Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, ARQT has a market cap of 3.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while ARQT trades at $28.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas ARQT's P/E ratio is 137.33. In terms of profitability, TLX's ROE is +0.07%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, TLX is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ARQT's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
TLX vs RLAY Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, RLAY has a market cap of 3.6B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while RLAY trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas RLAY's P/E ratio is -10.37. In terms of profitability, TLX's ROE is +0.07%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, TLX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RLAY's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
TLX vs SWTX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas SWTX's P/E ratio is -13.78. In terms of profitability, TLX's ROE is +0.07%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, TLX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check SWTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
TLX vs LEGN Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while LEGN trades at $18.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas LEGN's P/E ratio is -27.10. In terms of profitability, TLX's ROE is +0.07%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check LEGN's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
TLX vs AMLX Comparison October 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.6B. In comparison, AMLX has a market cap of 3.3B. Regarding current trading prices, TLX is priced at $10.69 on the NASDAQ, while AMLX trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 111.59, whereas AMLX's P/E ratio is -17.56. In terms of profitability, TLX's ROE is +0.07%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, TLX is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check AMLX's competition here